biosimilars

Predictions for biosimilars: How market access will play outEarly planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
What the new biosimilar means for U.S. healthcarePhysicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions.
Biosimilar naming method questionedFDA’s method for naming biosimilars and interchangeable biologics came under fire long before the first biosimilar, Zarxio, was approved last spring.
New biosimilar for RA to save millionsFDA’s approval of a new biosimilar—the third FDA-approved biosimilar—stands to save the US healthcare system millions of dollars.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.